Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jun 29:15:1023-1033.
doi: 10.2147/CIA.S227611. eCollection 2020.

Abaloparatide and the Spine: A Narrative Review

Jeremy C Thompson  1 , Nathan Wanderman  1 , Paul A Anderson  2 , Brett A Freedman  1
Affiliations
Review

Abaloparatide and the Spine: A Narrative Review

Jeremy C Thompson et al. Clin Interv Aging. .

Abstract

Osteoporosis is a common and debilitating condition characterized by diminished bone mass and architecture leading to bone fragility. Antiresorptive medicines like bisphosphonates (and less commonly denosumab) are the typical first-line agents for the medical treatment of osteoporosis. However, newer anabolic agents have been shown to improve bone mass and architecture, as well as reduce fracture risk, to a greater degree than traditional antiresorptive therapies. Teriparatide (human recombinant parathyroid hormone (PTH) 1-34, Forteo, Ely Lilly, Indianapolis, IN), which was the first in class to be approved in the United States, is the most widely used anabolic osteoporosis medicine and has shown significant benefit over traditional antiresorptive therapies. However, abaloparatide (synthetic parathyroid-related peptide (PTHrP), Tymlos, Radius Health, Waltham, MA), the second drug in this family, has recently become available for use. In this narrative review, we review the mechanism, effects, and benefits of abaloparatide compared to alternative treatments as well as discuss the current literature in regard to its effect on osteoporosis-related complications in the spine.

Keywords: Tymlos; abaloparatide; anabolic; osteoporosis; spine; teriparatide.

PubMed Disclaimer

Conflict of interest statement

Dr Paul A Anderson reports personal fees from Radius Medical, Amgen, Titan spine, Medtronic, Regeneration Technologies inc, outside the submitted work. The authors report no other conflicts of interest in this work.

Figures

Figure 1
Figure 1
Model of parathyroid hormone (PTH)/teriparatide and PTH-related peptide (PTHrP/abaloparatide activation of parathyroid hormone type 1 receptor (PTH1R)).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis - 2016. Endocr Pract. 2016;22(Suppl 4):1–42. doi:10.4158/EP161435.GL - DOI - PubMed
    1. Wright NC, Looker AC, Saag KG, et al. The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. J Bone Miner Res. 2014;29(11):2520–2526. doi:10.1002/jbmr.2269 - DOI - PMC - PubMed
    1. Wright NC, Saag KG, Dawson-Hughes B, Khosla S, Siris ES. The impact of the new National Bone Health Alliance (NBHA) diagnostic criteria on the prevalence of osteoporosis in the United States: supplementary presentation. Osteoporos Int. 2017;28(11):3283–3284. doi:10.1007/s00198-017-4207-9 - DOI - PubMed
    1. Cosman F, de Beur SJ, LeBoff MS, et al. Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014;25(10):2359–2381. doi:10.1007/s00198-014-2794-2 - DOI - PMC - PubMed
    1. Lehman RA, Kang DG, Wagner SC. Management of osteoporosis in spine surgery. J Am Acad Orthop Surg. 2015;23(4):253–263. doi:10.5435/JAAOS-D-14-00042 - DOI - PubMed

MeSH terms